Parabilis Medicines: Pioneering New Horizons in Cancer Treatment
Many proteins in the body are known to cause disease but remain stubbornly inaccessible to traditional drug treatment methods. Parabilis Medicines has developed a novel therapeutic modality designed to target such “untreatable” proteins. This innovative approach is being tested in various disease areas, with cancer as the initial focus. With its leading drug candidate poised for a pivotal clinical trial, Parabilis has entered the public markets, successfully raising $745 million to further fund its research efforts.
Strong Investor Confidence in Parabilis’ Strategy
Parabilis’ approach has resonated well with investors. After setting initial terms for its IPO, the company saw substantial interest, prompting it to increase the offering size twice in a single day. Initially, Parabilis proposed offering 33.3 million shares at a price range of $17 to $19 each. However, by the time the IPO was priced, the company offered 33.5 million shares at $20 each, raising $670 million. This was supplemented by an additional $75 million from a private placement with Regeneron Pharmaceuticals, bringing the total to $745 million. Parabilis’ shares debuted on the Nasdaq under the ticker symbol “PBLS.”
Targeting Elusive Disease-Causing Proteins
Many disease-associated proteins remain elusive due to their intracellular locations and flat surfaces, which hinder drug binding. Traditional small molecules can penetrate cells but struggle to bind to flat surfaces, whereas antibodies can bind to such surfaces but cannot penetrate cells. Parabilis’ solution involves engineered peptides with a distinctive alpha-helix structure, akin to a spiral. This structure is inspired by the natural use of alpha helices to bind to flat protein surfaces and penetrate cellular membranes. These alpha-helical peptides, termed helicons, can precisely target disease-causing proteins once inside the cell.
“Helicons combine the precision of antibodies and biologics with the intracellular access and tunability of small molecules in a single modality – enabling direct attack on historically inaccessible protein targets,” Parabilis explained in its IPO filing. “Our proprietary Helicon discovery platform allows us to integrate ligands and additional functionalities at multiple positions to precisely tune potency, selectivity, and pharmacological properties.”
Zolucatetide: A Promising Lead in Cancer Treatment
Parabilis’ lead program, Zolucatetide, is a helicon designed to inhibit a critical component of the Wnt/beta-catenin cell signaling pathway, which regulates cell proliferation and differentiation. Hyperactivation of this pathway is a well-known cancer trigger. The company has initially targeted desmoid tumors, a rare type of tumor developing in connective tissue. Currently, the only FDA-approved treatment for desmoid tumors is Ogsiveo, an oral small molecule with significant side effects, including severe diarrhea, rash, and ovarian dysfunction in many patients.
Parabilis aims to offer a more effective and tolerable treatment option for patients with desmoid tumors. A phase 1/2 study of intravenously infused Zolucatetide is underway. Among 25 evaluable patients, all demonstrated tumor reduction, with 74% showing an objective response and one patient achieving a complete response. The treatment has been safe and well-tolerated, with no treatment-related adverse events leading to study discontinuation.
Phase 3 testing of Zolucatetide in desmoid tumors is expected to commence in the first half of 2027. Parabilis is also exploring this drug in familial adenomatous polyposis (FAP), a rare condition characterized by precancerous polyps in the gastrointestinal tract. Additional studies are planned for other rare tumors, liver cancer, and colon cancer. The pipeline includes two preclinical helicons for prostate cancer, with plans to expand into other therapeutic areas.
From Academic Research to Public Markets
Parabilis was founded in 2015, based on research by Greg Verdine, a Harvard University chemistry professor and serial biotech entrepreneur. The in-licensed technology underpins Parabilis’ Helicon discovery platform, which uses AI and machine learning to identify suitable protein targets and develop helicons for them. Verdine served as CEO until 2023, succeeded by Mathai Mammen, a Johnson & Johnson veteran. The company, previously known as FogPharma, rebranded to Parabilis Medicines in 2024.
Parabilis has raised approximately $811.8 million in equity financing from its inception to its IPO, with its most recent funding being a $305 million Series F round in January. Fidelity Management & Research is the largest shareholder with a 7.3% post-IPO stake, followed by RA Capital Management at 6.5%.
Strategic Partnerships and Financial Outlook
In May, Parabilis and Regeneron initiated a partnership to utilize Helicon technology in developing Antibody Helicon Conjugates (AHCs), focusing on previously untreatable targets. Regeneron provided $50 million upfront and agreed to invest $75 million in Parabilis’ next equity financing, executed as a private placement concurrent with the IPO.
As of the first quarter, Parabilis reported a cash balance of $329 million. The company allocated $150 million for Zolucatetide’s clinical development in desmoid tumors, $120 million for other indications, and $190 million for other pipeline programs through Phase 1 trials. This funding, along with Regeneron’s upfront payment, should support operations through the second half of 2029.
[Updated with analyst comments.] Parabilis’ IPO marks a resurgence of biotech IPOs on Wall Street after a period of decline. April saw a record-breaking month for biotech IPOs, spearheaded by Kailera Therapeutics’ $625 million offering. “Now the Parabilis IPO sets a new record for the largest biotech IPO,” noted Ben Zercher, a senior biotech and pharmaceutical analyst at PitchBook. He highlights these companies as examples of mature biotechs ready for public offerings.
“As the biotech window reopens, IPO volume reflects a backlog of quality companies that continued to build during the biotech funding downturn, rather than a wave of hype,” Zercher commented. “While the pandemic-era class sold preclinical optionality, Parabilis and the 2026 cohort are priced on lower-risk clinical programs with clear regulatory pathways.”
For more information, see the original source Here.
“`
